bearish

Pharmaron Beijing Co Ltd-H

Pharmaron Beijing Co Ltd (3759.HK/300759.CH) - The Story May Have Changed

Due to overcapacity/fierce competition,Pharmaron is hard to achieve V-shaped rebound by the strategy of "integration".We are conservative about its margin/net profit growth.CGT CXO is the only way out

Equity Bottom-Up
240 Views, 26 Jul 2022 09:04
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • China Healthcare Weekly (Aug.5) - HK IPO, Innovent, BeiGene, the Largest IVD Centralized Procurement
    07 Aug 2022
  • Industry Report - Insights on China Companion Diagnostics Market (Business Logic and Outlook)
    03 Aug 2022
  • WuXi AppTec (603259.CH/2359.HK) 2022H1 - The Concerns Behind and the Outlook
    02 Aug 2022
  • Pharmaron Beijing Co Ltd (3759.HK/300759.CH) - The Story May Have Changed
    26 Jul 2022
  • Innovent Biologics Inc (1801.HK) - Innovent Is Not Optional but Necessary in Portfolio
    21 Jul 2022
  • 2022H2 China Healthcare Investment Strategy and Top Picks
    20 Jul 2022
  • China Healthcare Weekly (July.8)- CXO Outlook, 2022 NRDL Adjustment, Logic of Influenza Vaccine
    10 Jul 2022
  • Pharmaron Beijing Co Ltd (3759.HK/300759.CH) 2022/2021Q1 Results- Expectations Coexist with Concerns
    02 May 2022
x